<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00024050</url>
  </required_header>
  <id_info>
    <org_study_id>1536.00</org_study_id>
    <secondary_id>FHCRC-1536.00</secondary_id>
    <secondary_id>NCI-G01-2009</secondary_id>
    <secondary_id>CDR0000068887</secondary_id>
    <nct_id>NCT00024050</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for the Treatment of &quot;Less Advanced&quot; Myelodysplasi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Peripheral stem cell transplantation may be able to replace&#xD;
      immune cells that were destroyed by chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by peripheral&#xD;
      stem cell transplantation in treating patients who have myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the non-relapse toxicity and mortality on day 100 and at 1 year after&#xD;
           transplantation in patients with low or intermediate-risk myelodysplastic syndrome&#xD;
           treated with busulfan, cyclophosphamide, and allogeneic peripheral blood stem cell&#xD;
           transplantation.&#xD;
&#xD;
        -  Determine the incidence of donor stem cell engraftment and relapse-free survival in&#xD;
           these patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence and severity of acute and chronic graft-versus-host disease and&#xD;
           invasive fungal infections in these patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of relapse in these patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Peripheral blood stem cells (PBSC) or bone marrow are harvested from a related or&#xD;
      unrelated compatible donor. PBSC are selected for CD34+ cells.&#xD;
&#xD;
      Patients receive oral busulfan every 6 hours on days -7 to -4 and cyclophosphamide IV on days&#xD;
      -3 and -2. Allogeneic PBSC or bone marrow is infused on day 0.&#xD;
&#xD;
      As graft-versus-host disease prophylaxis, patients receive cyclosporine IV beginning on day&#xD;
      -1 and continuing orally twice daily (if feasible) until day 51 followed by a taper. Patients&#xD;
      also receive methotrexate IV on days 1, 3, 6, and 11.&#xD;
&#xD;
      Patients are followed through day 100, every 6 months for 2 years, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of low or intermediate-risk myelodysplastic syndrome&#xD;
&#xD;
               -  Refractory anemia (RA)&#xD;
&#xD;
               -  RA with ringed sideroblasts&#xD;
&#xD;
          -  No advanced myelodysplastic syndrome (i.e., at least 5% blasts in the marrow, more&#xD;
             than 1% blasts in the peripheral blood, or blasts in the cerebrospinal fluid)&#xD;
&#xD;
          -  No poor-risk cytogenetics (i.e., abnormalities of chromosome 7 or complex&#xD;
             abnormalities)&#xD;
&#xD;
          -  HLA-A, B, C, DRB1, and DQB1 compatible related or unrelated donor available&#xD;
&#xD;
               -  Mismatch for a single HLA-A, B, C, DRB1, or DQB1 allele allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  65 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST no greater than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 times upper limit of normal&#xD;
&#xD;
          -  Creatinine clearance at least 50%&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac insufficiency requiring treatment&#xD;
&#xD;
          -  No symptomatic coronary artery disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe hypoxemia (pO2 less than 70 mm Hg with DLCO less than 70% predicted)&#xD;
&#xD;
          -  No mild hypoxemia (pO2 less than 80 mm Hg with DLCO less than 60% predicted)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other disease that would limit life expectancy&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Joachim Deeg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 12, 2010</last_update_submitted>
  <last_update_submitted_qc>May 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2010</last_update_posted>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

